The drug acts by inhibiting the intracellular phosphorylation of HER2, leading to blockade of downstream MAPK and PI3K–Akt-signaling pathways, thereby impeding tumor cell growth and proliferation. The gene discussed is ERBB2; the disease is neoplasm.